NO991207L - Antifungal kombinasjonsterapi - Google Patents

Antifungal kombinasjonsterapi

Info

Publication number: NO991207L
Authority: NO; Norway
Prior art keywords: antifungal; inhibitors; combination therapy; combination; xmp
Prior art date: 1996-09-12

Application number

NO991207A

Other languages

English (en)

Norwegian (no)

Other versions

NO991207D0 (no

Inventor

Kenneth F Bartizal

George K Abruzzo

Amy M Flattery

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1999-03-11

Publication date

1999-05-11

1996-10-04 Priority claimed from GBGB9620739.4A external-priority patent/GB9620739D0/en

1999-03-11 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1999-03-11 Publication of NO991207D0 publication Critical patent/NO991207D0/no

1999-05-11 Publication of NO991207L publication Critical patent/NO991207L/no

Links

229940121375 antifungal agent Drugs 0.000 title abstract 6
230000000843 anti-fungal effect Effects 0.000 title abstract 3
238000002648 combination therapy Methods 0.000 title abstract 3
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 3
239000003429 antifungal agent Substances 0.000 abstract 3
239000003112 inhibitor Substances 0.000 abstract 3
OXVVQYCKEAJWFA-QVCGFCSKSA-N 10,12-dimethyl-tetradecanoic acid [3-(3-amino-1-hydroxy-propyl)-6-[1,2-dihydroxy-2-(4-hydroxy-phenyl)-ethyl]-11,20,21,25-tetrahydroxy-15-(1-hydroxy-ethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaaza-tricyclo[22.3.0.09,13]heptacos-18-yl]-amide Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OXVVQYCKEAJWFA-QVCGFCSKSA-N 0.000 abstract 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
229960003942 amphotericin b Drugs 0.000 abstract 2
150000003851 azoles Chemical class 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 abstract 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 abstract 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
229920002101 Chitin Polymers 0.000 abstract 1
229940123047 Elongation factor inhibitor Drugs 0.000 abstract 1
229920000057 Mannan Polymers 0.000 abstract 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 abstract 1
229930184499 Nikkomycin Natural products 0.000 abstract 1
229930182764 Polyoxin Natural products 0.000 abstract 1
229940098178 ambisome Drugs 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
229960004884 fluconazole Drugs 0.000 abstract 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract 1
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 abstract 1
229960004413 flucytosine Drugs 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
229960004130 itraconazole Drugs 0.000 abstract 1
229960004125 ketoconazole Drugs 0.000 abstract 1
150000002632 lipids Chemical group 0.000 abstract 1
229960002509 miconazole Drugs 0.000 abstract 1
WWJFFVUVFNBJTN-UHFFFAOYSA-N neopolyoxin C Natural products C=1C=C(O)C=NC=1C(O)C(C)C(N)C(=O)NC(C(O)=O)C(C(C1O)O)OC1N1C=CC(=O)NC1=O WWJFFVUVFNBJTN-UHFFFAOYSA-N 0.000 abstract 1
WWJFFVUVFNBJTN-VHDFTHOZSA-N nikkomycin Z Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)[C@H](NC(=O)[C@@H](N)[C@H](C)[C@H](O)C=2N=CC(O)=CC=2)C(O)=O)C=CC(=O)NC1=O WWJFFVUVFNBJTN-VHDFTHOZSA-N 0.000 abstract 1
-1 nikkomycins Natural products 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
230000035699 permeability Effects 0.000 abstract 1
229960001589 posaconazole Drugs 0.000 abstract 1
RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000002213 purine nucleotide Substances 0.000 abstract 1
239000002719 pyrimidine nucleotide Substances 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 abstract 1
OGGVRVMISBQNMQ-MDGIRFSOSA-N sordarin Chemical compound O[C@H]1[C@H](O)[C@H](OC)[C@@H](C)O[C@H]1OC[C@]1([C@@]2(C(C(C)C)=C3)C(O)=O)[C@H]3C[C@]2(C=O)[C@@H]2CC[C@@H](C)[C@H]2C1 OGGVRVMISBQNMQ-MDGIRFSOSA-N 0.000 abstract 1
OGGVRVMISBQNMQ-UHFFFAOYSA-N sordarin Natural products OC1C(O)C(OC)C(C)OC1OCC1(C2(C(C(C)C)=C3)C(O)=O)C3CC2(C=O)C2CCC(C)C2C1 OGGVRVMISBQNMQ-UHFFFAOYSA-N 0.000 abstract 1
BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
229960004740 voriconazole Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO991207A 1996-09-12 1999-03-11 Antifungal kombinasjonsterapi NO991207L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2632796P	1996-09-12	1996-09-12
GBGB9620739.4A GB9620739D0 (en)	1996-10-04	1996-10-04	Antifungal combination therapy
PCT/US1997/015987 WO1998010782A1 (en)	1996-09-12	1997-09-09	Antifungal combination therapy

Publications (2)

Publication Number	Publication Date
NO991207D0 NO991207D0 (no)	1999-03-11
NO991207L true NO991207L (no)	1999-05-11

Family

ID=26310166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO991207A NO991207L (no)	1996-09-12	1999-03-11	Antifungal kombinasjonsterapi

Country Status (21)

Country	Link
EP (1)	EP0925070B1 (cs)
JP (1)	JP3288051B2 (cs)
KR (1)	KR100380871B1 (cs)
CN (1)	CN1235554A (cs)
AT (1)	ATE248625T1 (cs)
AU (1)	AU721334B2 (cs)
CA (1)	CA2265824C (cs)
CY (1)	CY2481B1 (cs)
CZ (1)	CZ88499A3 (cs)
DE (1)	DE69724626T2 (cs)
DK (1)	DK0925070T3 (cs)
EA (1)	EA002469B1 (cs)
EE (1)	EE03748B1 (cs)
ES (1)	ES2203819T3 (cs)
IL (1)	IL128870A0 (cs)
NO (1)	NO991207L (cs)
NZ (1)	NZ334446A (cs)
PL (1)	PL333282A1 (cs)
PT (1)	PT925070E (cs)
SK (1)	SK29999A3 (cs)
WO (1)	WO1998010782A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2179403A1 (en) *	1994-11-08	1996-05-17	Jose Ramon Ruiz Gomez	Antifungal sordaridin derivatives
US6069126A (en) *	1996-09-12	2000-05-30	Merck & Co., Inc.	Antifungal combination therapy
AUPQ066399A0 (en)	1999-05-31	1999-06-24	Fujisawa Pharmaceutical Co., Ltd.	Antifungal combination use
AUPQ462399A0 (en) *	1999-12-13	2000-01-13	Fujisawa Pharmaceutical Co., Ltd.	New use
KR100680464B1 (ko) *	2000-06-28	2007-02-08	주식회사 하이닉스반도체	반도체 소자의 캐패시터 제조 방법
WO2002098463A1 (fr) *	2001-06-05	2002-12-12	The New Industry Research Organization	Compositions antifongiques
BRPI0607910A2 (pt) *	2005-04-07	2010-03-23	Toyama Chemical Co Ltd	composiÇço farmacÊutica para tratar infecÇÕes féngicas, e, mÉtodo de uso de um derivado de arilamidina ou um sal do mesmo
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
MX2009003533A (es)	2006-10-06	2009-07-17	Toyama Chemical Co Ltd	Composición farmacéutica que comprende derivado de fenilamidina y método para usar la composición farmacéutica en combinación con el aceite antifúngico.
TWI426918B (zh) *	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
US20110076240A1 (en) *	2008-04-18	2011-03-31	Day Donal F	Antifungal and Anti-Cariogenic Cellobio-Oligosaccharides Produced by Dextransucrase
CN102274217B (zh) *	2010-06-10	2013-04-10	吉林大学	三氯生作为抗真菌药物氟康唑增效剂的新用途
CN102274215B (zh) *	2010-06-10	2013-04-10	吉林大学	一种具有与氟康唑协同抗真菌作用的增效剂
CN102274216B (zh) *	2010-06-10	2013-04-10	吉林大学	一种提高氟康唑抗真菌作用的增效剂
US20130288956A1 (en)	2010-11-05	2013-10-31	Eisai R&D Management Co., Ltd.	Combined pharmaceutical composition as antifungal agent
US8623813B2 (en) *	2011-05-24	2014-01-07	Bayer Cropscience Lp	Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use
CN102319326A (zh) *	2011-07-23	2012-01-18	李玮	一种治疗脚癣的浸药卫生纸
CN114052029A (zh) *	2021-11-25	2022-02-18	兰州大学	具哌嗪和哌啶骨架的医用化合物在防治植物真菌病害中的用途
CN115721633B (zh) *	2022-03-25	2024-05-03	山东大学	羟基茜草素在作为t3ss小分子抑制剂中的应用
CN116473985B (zh) *	2023-03-29	2024-12-10	暨南大学	一种多烯类抗真菌药物组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5378804A (en) *	1993-03-16	1995-01-03	Merck & Co., Inc.	Aza cyclohexapeptide compounds

1997
- 1997-09-09 CZ CZ99884A patent/CZ88499A3/cs unknown
- 1997-09-09 DK DK97941495T patent/DK0925070T3/da active
- 1997-09-09 ES ES97941495T patent/ES2203819T3/es not_active Expired - Lifetime
- 1997-09-09 JP JP51380898A patent/JP3288051B2/ja not_active Expired - Fee Related
- 1997-09-09 AU AU43392/97A patent/AU721334B2/en not_active Ceased
- 1997-09-09 IL IL12887097A patent/IL128870A0/xx unknown
- 1997-09-09 PL PL97333282A patent/PL333282A1/xx unknown
- 1997-09-09 NZ NZ334446A patent/NZ334446A/xx unknown
- 1997-09-09 SK SK299-99A patent/SK29999A3/sk unknown
- 1997-09-09 CA CA002265824A patent/CA2265824C/en not_active Expired - Fee Related
- 1997-09-09 KR KR10-1999-7002052A patent/KR100380871B1/ko not_active Expired - Fee Related
- 1997-09-09 PT PT97941495T patent/PT925070E/pt unknown
- 1997-09-09 EE EEP199900088A patent/EE03748B1/xx not_active IP Right Cessation
- 1997-09-09 EA EA199900283A patent/EA002469B1/ru not_active IP Right Cessation
- 1997-09-09 WO PCT/US1997/015987 patent/WO1998010782A1/en not_active Ceased
- 1997-09-09 CN CN97199420A patent/CN1235554A/zh active Pending
- 1997-09-09 EP EP97941495A patent/EP0925070B1/en not_active Expired - Lifetime
- 1997-09-09 DE DE69724626T patent/DE69724626T2/de not_active Expired - Lifetime
- 1997-09-09 AT AT97941495T patent/ATE248625T1/de active
1999
- 1999-03-11 NO NO991207A patent/NO991207L/no not_active Application Discontinuation
2004
- 2004-10-27 CY CY0400076A patent/CY2481B1/xx unknown

Also Published As

Publication number	Publication date
EE03748B1 (et)	2002-06-17
EP0925070A1 (en)	1999-06-30
PT925070E (pt)	2003-12-31
EE9900088A (et)	1999-10-15
IL128870A0 (en)	2000-06-01
NZ334446A (en)	2000-11-24
CA2265824A1 (en)	1998-03-19
NO991207D0 (no)	1999-03-11
CZ88499A3 (cs)	1999-10-13
WO1998010782A1 (en)	1998-03-19
DK0925070T3 (da)	2003-12-01
JP2000503675A (ja)	2000-03-28
ES2203819T3 (es)	2004-04-16
DE69724626T2 (de)	2004-07-29
PL333282A1 (en)	1999-11-22
CA2265824C (en)	2004-11-09
JP3288051B2 (ja)	2002-06-04
EP0925070B1 (en)	2003-09-03
EA002469B1 (ru)	2002-06-27
EA199900283A1 (ru)	1999-08-26
AU721334B2 (en)	2000-06-29
SK29999A3 (en)	2000-02-14
ATE248625T1 (de)	2003-09-15
DE69724626D1 (de)	2003-10-09
CN1235554A (zh)	1999-11-17
AU4339297A (en)	1998-04-02
CY2481B1 (en)	2005-06-03
KR20000036054A (ko)	2000-06-26
KR100380871B1 (ko)	2003-04-18

Legal Events

Date	Code	Title	Description
2003-12-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DK0925070T3 (da)	2003-12-01	Antifungal kombinationsterapi
WO2000072865A3 (en)	2001-05-10	Antifungal combination use
Galgiani	1990	Fluconazole, a new antifungal agent
Bouma et al.	1997	Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors
ATE365487T1 (de)	2007-07-15	Verbesserungen an und bezüglich verstellbaren stühlen und betten
US6069126A (en)	2000-05-30	Antifungal combination therapy
Graybill	1988	Therapeutic agents
EP1157698A3 (en)	2002-05-02	Treatment of inflammatory diseases with oxypurine nucleosides
KR900700110A (ko)	1990-08-11	선암 치료용 전사효소 저해제
Kamisato et al.	1997	Involvement of intracellular cyclic GMP and cyclic GMP-dependent protein kinase in α-elastin-induced macrophage chemotaxis
Clark et al.	2012	The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C
IT1297538B1 (it)	1999-12-17	Enteroclisma di lattulosio/lattitolo con o senza aggiunta di neomicina per la cura della encefalopatia portosistemica acuta
Guideri et al.	2002	Oral low-dose dipyridamole protects from intravenous high-dose dipyridamole-induced ischemia. A stress echocardiographic study
HUP0000127A2 (hu)	2000-06-28	Több hatóanyagot tartalmazó antimikotikus kompozíció
Khan	2005	Effect of fluconazole on phagocytic response of polymorphonuclear leukocytes in a rat model of acute sepsis
KR20250102476A (ko)	2025-07-07	산화 아연 및 아졸계 화합물의 병용 요법을 이용한 피부 감염증의 치료 방법
MXPA99002401A (en)	1999-09-01	Antifungal combination therapy
TR200000728T2 (tr)	2000-09-21	Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
Calandra et al.	2003	Response to van Saene et al.'s comment on" Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients"
刘光第	1994	The Hybrid’s Dilemma
UCHIDA et al.	1976	Studies on the Antifungal Activities of 5-Flurocytosine 4. In Vitro and In Vivo Antitungal Activities against Dematiaceous Fungi
More et al.	0	A REVIEW OF STUDY OF ANTIFUNGAL AGENTS
BR0000161A (pt)	2001-03-13	Composição adequada para a inibição do crescimento de fungos, e, uso da combinação de um primeiro ingrediente que inibe a biogenese da parede da célula de um fungo normal e um segundo ingrediente que pode perturbar a estrutura da membrana celular do referido fungo.
AU9530101A (en)	2002-04-29	Medicinal composition and in particular its use in fluid therapy